Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics (NQ: NKTR )

16.48 USD -0.49 (-2.89%)
Official Closing Price Updated: 5:45 PM EDT, Oct 27, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,747,200
Open 16.56
Bid (Size) 16.18 (1)
Ask (Size) 17.85 (4)
Prev. Close 16.97
Today's Range 16.37 - 16.96
52wk Range 13.63 - 28.60
Shares Outstanding 171,402,476
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19
Study Designed to Evaluate Whether BEMPEG's Ability to Increase Lymphocyte Production Could Improve Treatment Regimens for COVID-19 Patients 
From PR Newswire
Vaccibody AS and Nektar Therapeutics Announce First Patient Dosed in a Phase 1/2a Study Arm Evaluating VB10.NEO, a Personalized Neoantigen Cancer Vaccine, with Bempegaldesleukin (NKTR-214) in Patients
Vaccibody AS and Nektar Therapeutics (NASDAQ: NKTR) today announced that the first patient has been dosed in the combination therapy of the Phase 1/2a study evaluating bempegaldesleukin (bempeg),... 
From PR Newswire

Performance

YTD
-21.37%
-21.37%
1 Month
-2.14%
-2.14%
3 Month
-28.93%
-28.93%
6 Month
-17.14%
-17.14%
1 Year
-6.89%
-6.89%

More News

Read More
Nektar Therapeutics Reports Second Quarter 2020 Financial Results
From PR Newswire
Nektar to Announce Financial Results for the Second Quarter 2020 on Thursday, August 6, 2020, After Close of U.S.-Based Financial Markets
From PR Newswire
Data Presented from Phase 1b Study of NKTR-358, a Novel T Regulatory Cell Stimulator, at Annual European Congress of Rheumatology (EULAR 2020)
From PR Newswire
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors During 2020 Virtual European Congress of Rheumatology (EULAR 2020)
From PR Newswire
Interesting NKTR Put And Call Options For December 18th
Tags Stocks
From Market News Video
Nektar Therapeutics Announces Publication of Results from Phase 1 Dose-Escalation Study for Bempegaldesleukin Plus Nivolumab in 'Cancer Discovery' Journal
From PR Newswire
PBE's Holdings Imply 31% Gain Potential
Tags ETFs
From ETF Channel
October 23rd Options Now Available For Nektar Therapeutics (NKTR)
Tags Stocks
From Market News Video
Analysts Expect IWS To Hit $88
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.